Semaglutide after pregnancy to lower heart and diabetes risk
Part of Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a weekly injection (semaglutide) to see if it can help lower the risk of heart disease and type 2 diabetes in women who recently had gestational diabetes. The goal is to improve long-term health after pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You gave birth within the last 6 weeks
- You are not currently breastfeeding or lactating
- You did not have diabetes before this pregnancy (no type 1 or type 2 diabetes)
- You have not had pancreatitis in the past
- You are not planning to get pregnant within the next year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether semaglutide can help women with prediabetes after past gestational diabetes return to better blood sugar levels and lower progression to diabetes. It is designed for women who are no longer breastfeeding and can use effective birth control.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.
This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
Hear when a new Gestational Diabetes Mellitus (GDM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.